India must prioritize product-led growth and innovation to compete with China's rapid advancements in biotechnology and AI.

Work AI leader Glean today announced an integration with Microsoft Agent 365, bringing Glean's secure, enterprise-grade AI directly into the daily flow of work for Microsoft 365 users. As a launch ...

Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the ...

Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for ...